Craving decrease with topiramate in outpatient treatment for cocaine dependence: an open label trial by Diehl, Alessandra et al.
Craving decrease with topiramate in outpatient 
treatment for cocaine dependence: an open label trial
Diminuição da fissura com topiramato no tratamento 
ambulatorial para dependência de cocaína: um ensaio 
clínico aberto
Abstract
Objective: To evaluate anticraving action and tolerability of topiramate in cocaine user treatment. Method: Male users of inhaled cocaine 
which met criteria for cocaine dependence (Diagnostic and Statistical Manual of Mental Disorders, fourth edition) were selected for 
outpatient 12-week, open label trial with topiramate; individual dosage ranged between 25-300 mg/day. Main clinical variables were 
abstinence rate, craving intensity, frequency and duration, adherence, dropouts, side effects and impulsivity measure through Barratt 
Impulsivity Scale. Patients received assertive strategic counseling for abstinence assistance and medication monitoring evaluation every 
two weeks. Comparative analysis was made with intention to treat, missing values were replaced (last observation carried forward), and 
significance level was 5%. Results: Adherence to treatment was 57% (at least three evaluations), 32% dropped out (one evaluation). 
There were no severe side effects. Negative test average was 25.4% (31.2). Significant reduction in craving intensity and duration was 
observed in 25% of the sample. No statistical significant reduction in craving frequency was observed in 7.1%. Increase in frequency 
was observed in 10.7% and 82.1% did not present any variation. No significant statistical variations in Barratt Impulsivity Scale or in 
the total score were found in the final evaluation when compared to baseline. Conclusion: More randomized placebo-controlled trials 
with topiramate for cocaine dependants should be performed to evaluate preliminary evidence.
Descriptors: Cocaine-related disorders; Behavior, addictive; Topiramate; Clinical trial [Publication type]; Clinical protocols
Resumo
Objetivo: Avaliar a ação anticraving e tolerabilidade do topiramato em usuários de cocaína. Método: Homens usuários de cocaína inalada 
que preenchiam critérios para dependência de cocaína (Manual Diagnóstico e Estatístico de Desordens Mentais, quarta edição) foram 
selecionados para 12 semanas de tratamento ambulatorial, em ensaio clínico aberto com topiramato; dosagens escalonadas entre 
25-300 mg/dia. As principais variáveis clínicas foram taxa de abstinência, intensidade, freqüência e duração do craving, aderência, 
perdas, efeitos colaterais e impulsividade medida por meio da Escala de Impulsividade Barratt. Os pacientes receberam estratégias 
assertivas de aconselhamento para manutenção da abstinência e monitoramento da medicação avaliada a cada duas semanas. 
Análises comparativas foram feitas com intenção de tratar, valores perdidos foram substituídos (última observação carregada ao final) e 
o nível de significância de 5%. Resultados: A aderência ao tratamento foi de 57% (pelo menos três avaliações), 32% de perdas (uma 
avaliação). Não houve efeitos colaterais graves. A média de testes negativos foi 25,4% (31,2). Significante redução na intensidade e 
duração do craving foi observada em 25% da amostra. Nenhuma redução significativa na freqüência do craving foi observada em 7,1%. 
Aumento na freqüência foi observado em 10,7% e 82,1% não apresentaram nenhuma variação. Nenhuma variação estatisticamente 
significativa na Escala de Impulsividade Barratt ou na pontuação total foi encontrada no final da avaliação quando comparado à inicial. 
Conclusão: Mais ensaios clínicos placebo-controlados com o topiramato para dependentes de cocaína deveriam ser conduzidos a fim 
de avaliar a evidência preliminar.
Descritores: Transtornos relacionados ao uso de cocaína; Comportamento, adicto; Topiramato; Ensaio clínico [Tipo de publicação]; 
Protocolos clínicos
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Introduction
Cocaine use causes an initial increase in dopamine and serotonin 
neurotransmission, responsible for pleasure and reinforcing drug 
effects. Neurotransmitter dysregulation during withdrawal plays an 
important role in craving.1
Given the magnitude and complexity of dependence, various 
pharmacological agents have been investigated with the intention 
of lessen craving abstinence intensity and acquirement. Recognition 
of dopamine neurotransmission in cocaine cerebral reward 
system encouraged clinical trials with dopaminergic agonists and 
antagonists; however, results were disappointing.1-3
Several pharmacological interventions (PI) have been studied for 
this condition, including dopaminergic agents, antidepressants, 5HT3 
antagonists, serotonergic agents, antiepileptics, amphetamines, 
GABAergic agents and miscellaneous drugs as naltrexone, nootropic 
agents, vaccines and dissulfiram. There is no evidence about the 
effectiveness of these medications in pharmacological cocaine-
dependence treatment.1-3
In spite of few controlled studies, topiramate (TPM), a drug initially 
used for some epilepsy types, has been found effective for chemical 
dependence treatment.4
Rubio (2002), Zullino (2002), Johnson (2003), Kampman 
(2004), and Bobes (2004) obtained favorable results with TPM 
in alcohol, opiate, benzodiazepine detoxification and cocaine 
dependents.5-9
TPM exercises its action by virtue of the GABAergic and 
glutamatergic system involvement in the cerebral reward system 
modulation. TPM exercises anticraving action through an increase 
in the GABAergic neurotransmission and inhibition of AMPA/kainate 
receptor activity.4
Considering the lack of substantial effective PI for cocaine 
dependence, this study, which is the first Latin American clinical trial 
with TPM in cocaine dependants, aims to add scientific evidence to 
the subject. Preliminary data indicates that controlled clinical trials 
in this area should be of further interest. 
This clinical trial aims to describe TPM anticraving effect and 
tolerability as an aid in cocaine-dependence treatment. The following 
clinical variables were considered: abstinence rate, craving intensity, 
frequency and duration, adherence, dropouts, side effects, and 
impulsivity measure using the Barratt Impulsivity Scale (BIS11). 
Method
Since this was a pilot open clinical trial involving inhaled cocaine 
dependents, a small sample was elected. Candidates were assisted 
with TPM in outpatient treatment for 12 weeks. The study was 
conducted at Uniad-Unifesp, from January through December 
2004. It was approved by the University Ethics Committee (protocol 
number 0699/03). Inclusion and exclusion criteria were applied to 
all patients who sought treatment. 
1. Inclusion criteria
Male patients, between 18-55 years of age, fulfilling DSM-IV 
diagnostic criteria for cocaine dependence, intranasal cocaine use, 
patient abstinence period of 7 days, permanent residents in São 
Paulo, volunteers in this clinical research, be able to read and sign 
consent forms.
2. Exclusion criteria
Hypersensitivity to TPM, exposure to other pharmacological agents 
12 months prior to the initial evaluation, kidney stones, since 1.5% 
of patients treated with TPM may develop this clinical condition, 
kidney failure history, serious mental disorders, patients using 
psychotropic drugs, patients using carbonic anhydrase inhibitors 
due to risk of developing kidney stones concomitant with TPM, 
uncontrolled hypertension, hepatic disease evidence, life-threatening 
situation in the investigator’s opinion, women due to possibility 
of reduction in oral contraceptive (OC) levels related to TPM use 
and consequent pregnancy risk during the treatment, since some 
initial TPM studies suggest that this drug could decrease estrogenic 
component of OC when used concomitantly.10
3. Procedures
Psychiatric clinical anamnesis, physical examination and 
assessment of instruments. Follow-up was performed every two 
weeks by two psychiatrists, urine test analysis and side effect 
assessment. Patients received assertive strategic counseling for 
abstinence assistance. An independent psychologist applied other 
scales in the 1st, 6th and 12th weeks of treatment.
4. Instruments
1) Urine Benzoylecgonine Test - rapid test: Visual, competitive 
immunoassay that can be used for benzoylecgonine qualitative 
detection (cocaine biotransformation product in the urine), cutoff 
300 ng/ml. Test sensitivity is 99% and specificity is 98%. Test does 
not identify intoxication level, nor does it reflect frequency or amount 
of drug used. It merely indicates presence or absence of the drug. 
The test generally detects cocaine use for 24 to 60 hours after last 
use. The widely accepted period for benzoylecgonine to be cleared 
from the urine is three to five days.11
2) Minnesota Cocaine Craving Scale (MCCS): Composed of five 
items which correspond to intensity, frequency, duration of craving, 
changes in relation to previous week and craving response to 
medication. We used the first three items of the scale (none 0 to 10 
maximum visual score analogue scale), since these items can be 
used independently, as it was done in other studies. A translation 
of the scale was used. Its internal consistency in this study showed 
an alpha Cronbach coefficient similar to that of other international 
studies (0.814).12
3) ASI: Semi-structured clinical interview which works as an 
intentional standard for addiction severity assessment. It consists of 
seven areas: medical, employment/support, drug and alcohol use, 
legal, family/social, and psychiatric. After each interview, a severity 
score was calculated based on the physician’s judgment and patient 
self-evaluation. Scores indicate whether problems exist in any of the 
areas assessed. ASI was submitted to validation and proved to have 
high rate of confidence and effectiveness.13
4) BIS11: Self-rating questionnaire, comprised of 30 Likert-
type questions, which provides a total score and three subscores: 
attention, nonplanning and motor. Scores vary from 30 to 120 
with no established cutoff point. The BIS11 was validated in Brazil 
for an adolescent sample and its score is a consistent measure of 
impulsiveness and has proven potential clinical use for measuring 
impulsiveness among selected patients.14
Attempting to minimize side effects, doses were scaled from 
small doses. The starting dose was 25 mg (25, 50 and 100 mg 
pills) increasing every 3 or 4 days to a maximum of 300 mg/day, 
according to assessment and clinical criteria of each psychiatrist to 
each individual. This seems to have clinically reduced side effects. 
Rate of abstinence considered was the number of negative tests 
divided by the total number of tests during the study. Adherence to 
treatment was defined as attendance to at least three consultations, 
which corresponded to half of the study (six weeks); aiming to obtain 
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a more reliable time to observe clinical results. Research subjects who 
did not appear for the second consultation were considered dropouts. 
Comparative analysis was performed with intention to treat and the 
missing values were replaced by LOCF. Paired t test (parametric) was 
used to compare craving intensity (quantitative variable) baseline 
results to final evaluation through MCCS and BIS11. The Wilcoxon test 
(nonparametric), which takes the categorized magnitude of increase 
and decrease variables into consideration, was used to evaluate both 
dependant groups (baseline and final) in relation to craving duration 
and frequency. Confidence interval 95% was calculated to frequent 
adverse effects. Statistical significance level 0.05 (α = 5%). 
Results
The sample was composed of 28 male subjects, mean age of 30.39 
years (6.74), and average for dependence symptoms was 6.08 (1.22). 
The average number of symptoms of abstinence syndrome was 3.24 
(1.09) (Table 1). 
Twelve subjects (43%) tested negative in urine screenings. Average 
negative result rate throughout tests was 25.4% (31.2). Reduction 
in craving intensity was observed: 7.32 (2.26) in baseline and 6.14 
(2.98) in final evaluation (p1 = paired, t = 0.012), 25% had significant 
reduction and 75% did not have significant alteration.
The same occurred with craving duration: 25% had reduction, while 
75% did not have changes (p2 = Wilcoxon test = 0.018).
Reduction was not found in craving frequency (p2 = 0,783): 7.1% 
had reduction in frequency; 10.7% related an increase in frequency 
and 82.1% did not.
Dropout rate in this clinical trial corresponded to 32% and adherence 
was 57%. Average consultation number was 3.14 (1.80). 
Average TPM dose was 127.27 (93.19) mg/day. The highest 
percentage of tolerability dosage was 100 mg/day, which corresponds 
to 68.2% of research subjects. 
Main adverse effect with incidence above 10% was included: 
somnolence (68%, IC = 46.0-84.6), paresthesia (63%, IC = 41.0-
80.9), concentration deficit (47%, IC = 27.3-68.3), xerostomia 
(21%, IC = 8.5-43.3), anorexia (16%, IC = 5.5-37.6), and polyuria/
polydipsia (16%, IC = 5.5-37.6). Nineteen subjects were 
analyzed, since nine patients failed to appear for the second 
medical evaluation. Incidence of adverse events was mild.
Statistical significant variation was found neither regarding use 
of BIS11 nor in the final results compared to baseline: BIS11 total 
mean (SD) was 76.75 (9.24) at baseline and 75.86 (10.46) 
in the final result (p = 0.474).
Discussion
A statistically significant finding in this clinical trial was a 
decrease in craving intensity and duration. The main clinical 
implication of this result is that TPM seems to reduce craving, 
which is one of the main factors related to relapses in drug 
dependence. 
So far, no medication has been approved for the specific 
indication of “anticraving,” and indeed, even the concept of 
craving is controversial. In clinical trials, however, reductions 
in craving usually predict reduced drug use or maintenance of 
abstinence. Craving has been measured in a variety of ways, 
from a 100 mm Likert scale to a more complex questionnaire. 
Some have argued that “craving” is not a useful concept, and 
certainly, no one would claim that drug use never occurs without 
a conscious craving or that craving always leads to drug use. 
Some compulsive drug use has an automatic quality without a 
conscious buildup of desire. Yet most former addicts recognize a 
state of intense desire for drugs that is triggered by environmental 
cues or appear spontaneously. Despite the controversy, craving 
has been measured in many clinical trials.1 
One limitation in this trail was that decrease in craving was 
significant, but this was an open trail without placebo or control 
group. Therefore, there is a possibility that reduced craving 
only occurred due to the fact that, after 12 weeks, craving is 
expected to decrease. Another limitation was the small number 
of subjects and an all-male sample. As a result, the sample does 
not represent all current cocaine users in treatment centers.
Only 25.4% obtained abstinence acquisition. Nevertheless, 
it is important to emphasize that a negative quality in urine 
screening is a conservative outcome measure to evaluate 
abstinence rate.
However, the most mentioned side effects were present in 
more than half of the sample. Side effects were mild and there 
were none that would limit drug use or losses. In these cases, a 
slow dose titration prevented the troublesome TPM side effects. 
Overall, adverse event profile was similar to that reported for 
other indications.10
Clinical trials in chemical dependents used to have high 
dropout rates, which very often compromised data extrapolation. 
The 32% dropout rate was similar to other clinical trials with the 
same profile and reasonable for a study that was not coupled to 
psychosocial intervention.15
With regard to impulsivity measure, no statistically relevant 
variations were found on the BIS11. Longer observation time 
may demonstrate some alterations in this sense.
It seems important that future clinical trials include multiple 
psychoactive substance users, larger samples, longer follow-up 
and women, as commonly found in outpatient clinics. This would 
increase power of evidence and capacity of generalization. 
Conclusion 
No pharmacological treatment has yet proven to be broadly 
effective for cocaine dependence. This study, as other recent 
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clinical trials, highlights TPM as a potential medication for reduction 
of craving and use in cocaine dependants. However, a larger 
randomized placebo-controlled trial with TPM in a less selective 
cocaine-dependant sample should be performed to evaluate 
preliminary evidence.
Future studies should consider the inclusion of psychiatric 
comorbidity and the association of psychosocial treatment. 
Acknowledgments
We would like to thank UNIAD for providing adequate approval for conducting 
this study, as well as the colleagues who contributed to the accomplishment 
of this clinical trial. 
References 
1.  O’Brien CP. Anticraving medications for relapse prevention: a 
possible new class of psychoactive medications. Am J Psychiatry. 
2005;162(8):1423-31.
2.  Vocci FJ, Elkashef A. Pharmacotherapy and other treatments for cocaine 
abuse and dependence. Curr Opin Psychiatry. 2005,18(3):265-70.
3.  Sofuoglu M, Kosten TR. Emerging pharmacological strategies in 
the fight against cocaine addiction. Expert Opin Emerging Drugs. 
2006;11(1):91-8.
4.  Sofuoglu M, Kosten TR. Novel approaches to the treatment of cocaine 
addiction. CNS Drugs. 2005;19(1):13-25.
5.  Rubio G, Ponce G, Jimenez-Arriero MA, Palomo T, Ferre F. Effectiveness 
of topiramate in control of alcohol craving. Eur Neuropsychopharmacol. 
2002;12(Suppl 2):S63.
6.  Zullino DF, Cottier AC, Besson J. Topiramate in opiate withdrawal. 
Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(6):1221-3.
7.  Johnson BA, Ait-Daoud N, Bowden CL, DiClemente C, Roache 
JD, Lawson K, Javors MA, Ma JZ. Oral topiramate for treatment 
of alcohol dependence: a randomized controlled trial. Lancet. 
2003;361(9370):1677-85.
8.  Kampman KM, Pettinati H, Lynch KG, Dackis C, Sparkman T, Weigley 
C, O’Brien CP. A pilot trial of topiramate for the treatment of cocaine 
dependence. Drug Alcohol Depended. 2004;75(3):233-40.
9.  Bobes J, Carreño JE, Gutiérrez CE, San Narciso GI, Antuña MJ, Díaz 
T, Fernández JJ, Cerceda A, Alvarez CE, Marina P, García-García 
M. Study of effectiveness of craving control with topiramate in 
patients with substance dependence disorders. Actas Esp Psiquiatr. 
2004;32(5):299-306.
10.  Topamax (Topiramate). Available URL: http://www.topamax.com/
topamax/index.html Accessed 16/04/2008.
11.  Delucchi KL, Jones RT, Batki SL. Measurement properties of 
quantitative urine benzoylecgonine in clinical trials research. Addiction. 
1997;92(3):297-302.
12.  Focchi GR, Leite Marcos da C, Scivoletto Sandra. Use of the 
dopaminergic agonist pergolide in the treatment of cocaine craving. 
Rev Bras Psiquiatr. 2001;23(4):188-94.
13.  McLellan AT, Luborsky L, Cacciola J, Griffith J, Evans F, Barr HL, 
O’Brien CP. New data from the addiction severity index: reliability and 
validity in three centers. J New Ment Dis. 1985;173(7):412-23.
14.  von Diemen L, Szobot CM, Kessler F, Pechansky F. Adaptation 
and construct validation of the Barratt Impulsivity Scale BIS 11 to 
Brazilian Portuguese for use in adolescents. Rev Bras Psiquiatr. 
2007;29(2):153-6.
15.  Elkashef A, Holmes TH, Bloch DA, Shoptaw S, Kampman K, Reid 
MS, Somoza E, Ciraulo D, Rotrosen J, Leiderman D, Montgomery 
A, Vocci F. Retrospective analyses of pooled data from CREST I and 
CREST II trails for treatment of cocaine dependence. Addiction. 2005; 
100(Suppl 1):91-101.
Artigo06_2524_V03.indd   135 28/5/2008   16:47:44
